Generic placeholder image

Current Alzheimer Research

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Neuropeptides in Alzheimer’s Disease: From Pathophysiological Mechanisms to Therapeutic Opportunities

Author(s): Debby Van Dam, Annemie Van Dijck, Leen Janssen and Peter Paul De Deyn

Volume 10, Issue 5, 2013

Page: [449 - 468] Pages: 20

DOI: 10.2174/1567205011310050001

Price: $65

Abstract

Neuropeptides are found throughout the entire nervous system where they can act as neurotransmitter, neuromodulator or neurohormone. In those functions, they play important roles in the regulation of cognition and behavior. In brain disorders like Alzheimer’s disease (AD), where abnormal cognition and behavior are observed, the study of neuropeptides is particularly interesting since altered neuropeptides can function as biomarkers or as targets for new medication. In this article neuropeptides with relevance to AD are listed and their influence on cognitive and behavioral disturbances is discussed. Findings from human cerebrospinal fluid and brain tissue, and AD mouse models are described and related to the pathophysiology and symptomatology of the disease. In the past, clinical trials with neuropeptides have often failed due to insufficient delivery to the brain. Therefore, new strategies to target the brain with peptide drugs are also covered.

Keywords: Behavior, blood-brain barrier, clinical trial, cognition, drug delivery systems, pathophysiology, therapy.

Next »

Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy